Peter Nørkjær Laursen

Medical doctor with a passion for life science and drug development and driven by improving the lives of patients. Experience in the pharmaceutical industry through various roles

1. “Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study”

Laursen PN, Holmvang L, Lønborg J, Køber L, Høfsten DE, Helqvist S, Clemmensen P, Kelbæk H, Jørgensen E, Lassen JF, Pedersen F, Høi-Hansen T, Therkelsen CJ, Tilsted HH, Jensen LO, Nepper-Christensen L, Sadjadieh G, Engstrøm T. Am J Cardiol. 2018 Oct 15;122(8):1287-1296.

2. “Unreported exclusion and sampling bias in interpretation of randomized controlled trials in patients with STEMI.”

Laursen PN, Holmvang L, Lønborg J, Køber L, Høfsten DE, Helqvist S, Clemmensen P, Kelbæk H, Jørgensen E, Lassen JF, Pedersen F, Høi-Hansen T, Raungaard B, Terkelsen CJ, Jensen LO, Sadjadieh G, Engstrøm T. Int J Cardiol. 2019 Aug 15;289:1-5. doi: 10.1016/j.ijcard.2019.04.064. Epub 2019 May 1.

3. “Drop-out from cardiovascular magnetic resonance in a randomized controlled trial of ST-elevation myocardial infarction does not cause selection bias on endpoints”

Laursen PN, Holmvang L, Kelbæk H, Vejlstrup N, Engstrøm T, Lønborg J. Clin Res Cardiol. 2017 Jul;106(7):525-532.

4. “Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients”

Sadjadieh G, Engstrøm T, Høfsten DE, Helqvist S, Køber L, Pedersen F, Laursen PN, Andersson HB, Nepper-Christensen L, Clemmensen P, Sørensen R, Jørgensen E, Saunamäki K, Tilsted HH, Kelbæk H, Holmvang L. Am J Cardiol. 2018 Oct 15;122(8):1287-1296. doi: 10.1016/j.amjcard.2018.07.008. Epub 2018 Jul 19.

5. “Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy)”

Sadjadieh G, Engstrøm T, Helqvist S, Høfsten DE, Køber L, Pedersen F, Laursen PN, Nepper-Christensen L, Clemmensen P, Møller-Helgestad OK, Sørensen R, Ravkilde J, Terkelsen CJ, Jørgensen E, Saunamäki K, Tilsted HH, Kelbæk H, Holmvang L. Am J Cardiol. 2018 Apr 1;121(7):781-788.

6. “Importance of elevated heart rate in the very early phase of ST-segment elevation myocardial infarction: Results from the DANAMI-3 trial”

Nepper-Christensen L, Lønborg J, Ahtarovski KA, Høfsten DE, Kyhl K, Schoos MM, Göransson C, Laursen PN, Sadjadieh G, Ghotbi AA, Bertelsen L, Køber L, Helqvist S, Pedersen F, Jørgensen E, Kelbæk H, Vejlstrup N, Holmvang L, Engstrøm T. Eur Heart J Acute Cardiovasc Care. 2019 Jun;8(4):318-328.

7. “Validation of the all-comers design: Results of the TARGET-AC substudy”.

G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Am Heart J. 2020 Mar;221:148-154.

8. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.

Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, Varbo A, Wilding JPH, Wallenstein

9. “The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding”

Sørensen B, Tang M, Larsen OH, Laursen PN, Fenger-Eriksen C, Rea CJ. Thromb Res. 2011;128 Suppl 1:S13-6.

10. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators.

Lancet. 2023 Aug 26;402(10403):705-719.

11. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Wilkinson L, Holst-Hansen T, Laursen PN, Rinnov AR, Batterham RL, Garvey WT.Obesity (Silver Spring). 2023 Sep;31(9):2249-2259.

12. Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.

McGowan BM, Houshmand-Oeregaard A, Laursen PN, Zeuthen N, Baker-Knight J.Obesity (Silver Spring). 2023 Apr;31(4):990-999.

13. Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a retrospective cohort study in the UK.

Haase CL, Varbo A, Laursen PN, Schnecke V, Balen AH.Hum Reprod. 2023 Mar 1;38(3):471-481.